Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18965854 | 0.83 | F10 (0.46) | F10KLKB1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL18960439 | 0.82 | NPC1 (0.44) | F10KLKB1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL17488012 | 0.81 | HDAC1 (0.52) | F10KLKB1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL18960433 | 0.78 | NPC1 (0.50) | RAB9ASMN1; SMN2NPC1KMT2ATP53 | |
| SCHEMBL17488172 | 0.77 | CYP3A4 (0.54) | RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL18960407 | 0.77 | NPC1 (0.59) | RAB9ASMN1; SMN2NPC1KMT2ATP53 | |
| SCHEMBL21660948 | 0.77 | NPC1 (0.56) | RAB9ASMN1; SMN2NPC1KMT2ATP53 | |
| SCHEMBL18960434 | 0.77 | NPC1 (0.48) | RAB9ASMN1; SMN2NPC1KMT2ATP53 | |
| SCHEMBL18960437 | 0.77 | NPC1 (0.48) | RAB9ASMN1; SMN2NPC1KMT2ATP53 | |
| SCHEMBL17488146 | 0.76 | NPC1 (0.49) | RAB9ASMN1; SMN2NPC1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | F10 1550/4885KLKB1 4308/4885RAB9A 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.